Bioxel Gets Considerable Paclitaxel Order

Bioxel Pharma received a paclitaxel order valued at $700,000 from a generic manufacturer in the EU. The order will be used in a generic paclitaxel drug currently marketed in Europe. Product deliveries under the order will begin this quarter.

“This is the second major paclitaxel order for Bioxel in the past month,” said Pascal Delmas, president and chief executive officer of Bioxel. “We are clearly earning customer confidence and building revenue momentum with a combination of product quality, availability and value. Since June, Bioxel has landed major Paclitaxel orders with both leading generic and second generation taxane manufacturers that total $1.8 million.”

Bioxel’s product meets the new European quality standards, effective since July 2007. Bioxel’s Drug Master File (DMF), which is registered in more than 25 countries including the U.S., Canada, and Europe, allows the company to sell paclitaxel throughout this territory.